Experience with vincristine - associated neurotoxicity
View/ Open
Date
2001Author
Abinya, Nicholas O
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
OBJECTIVES:
To evaluate the frequency and severity of occurrence of vincristine-associated neurotoxicity.
DESIGN:
A retrospective case series study.
SETTING:
Hurlingham Oncology Clinic, Nairobi.
SUBJECTS:
Thirty-eight patients treated for various neoplasms with vincristine containing chemotherapeutic regimens.
MAIN OUTCOME MEASURES:
The frequency and degree of neurotoxicity when vincristine was given at the standard dose of 1.4 mg/m2.
RESULTS:
Five patients (13.2%) developed peripheral neuropathy, one having had it even before vincristine was started. Therefore only four (10.5%) had it attributed to vincristine. Four of the patients who developed neuropathy (80%) were HIV-positive. Neuropathy grade 2 (severe) occurred in only two patients leading to discontinuation of the drug. All the neurotoxicity resolved after discontinuation of vincristine.
CONCLUSION:
Vincristine induced neuropathy occurred but was rarely severe at a dose of 1.4 mg/m2. It appeared to be more frequent in HIV infected individuals, but controlled studies with bigger sample sizes are required to determine whether this may warrant routine capping of the dose at a maximum of 2 mg.
URI
http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/51525http://www.ncbi.nlm.nih.gov/pubmed/11957264
Citation
Abinya, NAO, Nyabola IO. 2001. Experience with vincristine - associated neurotoxicity.Publisher
University of Nairobi College of Health science
Collections
- Faculty of Health Sciences (FHS) [10387]